STAT1-Induced HLA class I Upregulation Enhances Immunogenicity and Clinical Response to anti-EGFR mAb Cetuximab Therapy in HNC Patients

Documenti analoghi

• STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
  di: Srivastava, Raghvendra M, et al.
  Pubblicazione: (2013)
• CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients
  di: Srivastava, Raghvendra M., et al.
  Pubblicazione: (2016)
• Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells
  di: Concha-Benavente, Fernando, et al.
  Pubblicazione: (2016)
• Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients
  di: Trivedi, Sumita, et al.
  Pubblicazione: (2016)
• EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
  di: Concha-Benavente, Fernando, et al.
  Pubblicazione: (2013)